浙江骏德生物科技

Junde Bio is a biopharmaceutical company based in Zhejiang, China, specializing in the development of innovative metabolic and endocrine therapies. The company focuses on leveraging its proprietary oral peptide delivery platform to transform injectable treatments into convenient oral formulations. Its primary research and development efforts are directed toward multi-target agonists, including GLP-1, GIP, and Glucagon receptor modulators, for the treatment of obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Junde Bio aims to address significant unmet medical needs in the metabolic disease space through advanced formulation technology and drug design.